Cerebrospinal Fluid CXCL13 Concentration for Diagnosis of Neurosyphilis: a Systematic Review and Meta-analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 May 31

PMID 38821573

Authors

Fang-Zhi Du

Xu Zhang

Xiao-Li Zheng

Rui-Li Zhang

Qian-Qiu Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To systematically assess the diagnostic accuracy of CXCL13 testing of cerebrospinal fluid (CSF) for neurosyphilis diagnosing.

Design: Systematic review and meta-analysis.

Data Sources: PubMed, Embase, Cochrane Library and Web of Science databases from their inception until 1 May 2023.

Eligibility Criteria: Both cross-sectional and case-control diagnostic test studies evaluating the diagnostic value of CSF CXCL13 in diagnosing neurosyphilis were included, with no language restrictions.

Data Extraction And Synthesis: Two researchers extracted data independently from all finally included articles. The updated Quality Assessment of Diagnostic Accuracy Studies tool was used to assess the quality of the included studies. Quantitative synthesis was done using a bivariate random-effects model.

Results: This meta-analysis included seven eligible studies involving a total of 1152 patients with syphilis and 430 patients with neurosyphilis. The pooled sensitivity, specificity and summary area under the curve (AUC) of CSF CXCL13 testing for the diagnosis of neurosyphilis were 0.76 (95% CI 0.64 to 0.85; I=82%), 0.83 (95% CI 0.80 to 0.85; I=32.29%) and 0.84 (95% CI 0.81 to 0.87), respectively. Sensitivity analysis confirmed the stability of the combined results. Meta-regression analysis revealed that the heterogeneity of pooled sensitivity was related to different study regions; subgroup analysis indicated that the diagnostic value of CSF CXCL13 testing reported in studies from China was superior to that reported in non-Chinese studies (pooled sensitivity, specificity and summary AUC values were 0.84 I=0) vs 0.64 (I=79.53%), 0.83 (I=42.03%) vs 0.83 (I=32.87%) and 0.87 vs 0.83, respectively). The diagnostic value reported in studies with a sample size ≥200, unclassified neurosyphilis and HIV-negative subgroups was superior to the total combined value.

Conclusions: This meta-analysis has demonstrated a reasonable level of accuracy for diagnosis of neurosyphilis with CSF CXCL13 testing. Further multicentre, prospective diagnostic studies, especially in asymptomatic neurosyphilis and HIV-infected patients, are needed to provide more evidence for evaluation before clinical application.

Prospero Registration Number: CRD42023414212.

References

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

Leeflang M . Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect. 2013; 20(2):105-13. DOI: 10.1111/1469-0691.12474. View

Tang W, Huang S, Chen L, Yang L, Tucker J, Zheng H . Late Neurosyphilis and Tertiary Syphilis in Guangdong Province, China: Results from a Cross-sectional Study. Sci Rep. 2017; 7:45339. PMC: 5364404. DOI: 10.1038/srep45339. View

Swiderek-Matysiak M, Oset M, Domowicz M, Galazka G, Namiecinska M, Stasiolek M . Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement. Biomedicines. 2023; 11(2). PMC: 9953577. DOI: 10.3390/biomedicines11020425. View

Wang C, Wu K, Yu Q, Zhang S, Gao Z, Liu Y . CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients. Sci Rep. 2016; 6:33569. PMC: 5030708. DOI: 10.1038/srep33569. View

Marra C . Alternatives to the Cerebrospinal Fluid Venereal Disease Research Laboratory Test for Neurosyphilis Diagnosis. Sex Transm Dis. 2021; 48(8S):S54-S57. PMC: 8514150. DOI: 10.1097/OLQ.0000000000001450. View

Pilz G, Sakic I, Wipfler P, Kraus J, Haschke-Becher E, Hitzl W . Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction. Fluids Barriers CNS. 2020; 17(1):7. PMC: 7038591. DOI: 10.1186/s12987-020-0170-5. View

Zeng Y, Lin Y, Zhang N, Zou C, Zhang H, Peng F . CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients. Springerplus. 2016; 5(1):743. PMC: 4909691. DOI: 10.1186/s40064-016-2462-4. View

Li D, Huang X, Shi M, Luo L, Tao C . Diagnostic role of CXCL13 and CSF serology in patients with neurosyphilis. Sex Transm Infect. 2021; 97(7):485-489. DOI: 10.1136/sextrans-2020-054778. View

10.

Leth T, Dessau R, Moller J . Discriminating between Lyme neuroborreliosis and other central nervous system infections by use of biomarkers CXCL13 and IL-6. Ticks Tick Borne Dis. 2022; 13(5):101984. DOI: 10.1016/j.ttbdis.2022.101984. View

11.

Xie J, Wang M, Zheng Y, Lin Y, He Y, Lin L . Performance of the nontreponemal tests and treponemal tests on cerebrospinal fluid for the diagnosis of neurosyphilis: A meta-analysis. Front Public Health. 2023; 11:1105847. PMC: 9932918. DOI: 10.3389/fpubh.2023.1105847. View

12.

Mothapo K, Verbeek M, van der Velden L, Ang C, Koopmans P, van der Ven A . Has CXCL13 an added value in diagnosis of neurosyphilis?. J Clin Microbiol. 2015; 53(5):1693-6. PMC: 4400737. DOI: 10.1128/JCM.02917-14. View

13.

Xie L, Li W, Ye W, Xiao Y, Ke W, Niu J . Serum Ubiquitin C-Terminal Hydrolase-L1, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain Are Good Entry Points and Biomarker Candidates for Neurosyphilis Diagnosis Among Patients Without Human Immunodeficiency Virus to Avoid Lumbar.... Clin Infect Dis. 2023; 77(3):472-479. DOI: 10.1093/cid/ciad158. View

14.

Du F, Zhang H, Li J, Zheng Z, Zhang X, Zhang R . Neurosyphilis in China: A Systematic Review of Cases From 2009-2021. Front Med (Lausanne). 2022; 9:894841. PMC: 9136070. DOI: 10.3389/fmed.2022.894841. View

15.

Marra C, Tantalo L, Sahi S, Maxwell C, Lukehart S . CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis. 2010; 37(5):283-7. PMC: 2884158. DOI: 10.1097/OLQ.0b013e3181d877a1. View

16.

Quintero-Moreno J, Valencia-Vasquez A, Aguirre-Castaneda C . [Clinical and socio-demographic profile of neurosyphilis: a retrospective study in a reference centre in Colombia]. Rev Neurol. 2019; 69(2):53-58. DOI: 10.33588/rn.6902.2018381. View

17.

Yu Q, Cheng Y, Wang Y, Wang C, Lu H, Guan Z . Aberrant Humoral Immune Responses in Neurosyphilis: CXCL13/CXCR5 Play a Pivotal Role for B-Cell Recruitment to the Cerebrospinal Fluid. J Infect Dis. 2017; 216(5):534-544. DOI: 10.1093/infdis/jix233. View

18.

Yang L, Fu Y, Li S, Liu C, Liu D . Analysis of DNA and CXCL13 in Cerebrospinal Fluid in HIV-Negative Syphilis Patients. Infect Drug Resist. 2023; 15:7791-7798. PMC: 9807064. DOI: 10.2147/IDR.S394581. View

19.

Xu M, Rui D, Yan Y, Xu S, Niu Q, Feng G . Oxidative Damage Induced by Arsenic in Mice or Rats: A Systematic Review and Meta-Analysis. Biol Trace Elem Res. 2016; 176(1):154-175. DOI: 10.1007/s12011-016-0810-4. View

20.

Gao Z, Gou Y, Liu X, Peng L . Advances in laboratory diagnostic methods for cerebrospinal fluid testing for neurosyphilis. Front Public Health. 2022; 10:1030480. PMC: 9703065. DOI: 10.3389/fpubh.2022.1030480. View